Trials / Terminated
TerminatedNCT01957709
Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma
A Pilot Study to Test Whether Systemic Interferon Gamma Increases Tumor Class I MHC Expression in Patients With Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
- Status
- Terminated
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Fred Hutchinson Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This pilot clinical trial studies the effect of recombinant interferon gamma on tissue in treating patients with soft tissue sarcoma. Interferon gamma may interfere with the growth of tumor cells.
Detailed description
PRIMARY OBJECTIVES: I. To determine whether systemic administration of interferon (IFN) gamma (recombinant interferon gamma) will increase class I major histocompatibility complex (MHC) expression in synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCL) tumors. SECONDARY OBJECTIVES: I. To determine whether systemic administration of IFN gamma will increase class II MHC expression in SS and MRCL tumors. II. To examine changes in the immune response to MRCL and SS by examining changes in the immune infiltrates, antibody response and antigen specific T cell response before and after IFN gamma treatment. OUTLINE: Patients receive recombinant interferon gamma subcutaneously (SC) every 7 days for 4 weeks before surgery. After completion of study, patients are followed up at 2 weeks post-surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Laboratory Biomarker Analysis | Correlative studies |
| BIOLOGICAL | Recombinant Interferon Gamma | Given subcutaneously weekly for four weeks prior to surgery. |
Timeline
- Start date
- 2013-09-25
- Primary completion
- 2018-06-01
- Completion
- 2018-06-01
- First posted
- 2013-10-08
- Last updated
- 2019-07-10
- Results posted
- 2019-07-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01957709. Inclusion in this directory is not an endorsement.